Recently, SCD-1 has emerged as a potential therapeutic target since the inhibition of its activity or the silencing of its expression decreases proliferation in lung, colon, gastric, prostate, and breast cancer cell lines [18–26] and tumor formation in xenograft models [18, 24, 27]. The gene discussed is SCD; the disease is breast carcinoma.